Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p7
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 7/31)
Character Range: 20939–24710

syringe
     insert:
   Powder for injection 1,200,000 units with diluent 5 mL (S19A)  Injection     Benzylpenicillin Benzathine (Brancaster Pharma, UK)  OJ  MP NP PDP        10  0  1

     [23]               Schedule 1, Part 1, entry for Bortezomib in the form Powder for injection 3.5 mg
     omit:
            Bortezomib-AFT   AE   MP   C11099 C13745      See Note 3   See Note 3   1      D(100)

     [24]               Schedule 1, Part 1, entry for Cefaclor in the form Powder for oral suspension 250 mg (as monohydrate) per 5 mL, 75 mL
         (a)           omit:
         a  APO-Cefaclor  TX  PDP        1  0  1

         (b)           omit:
         a  APO-Cefaclor  TX  MP        1  1  1

     [25]               Schedule 1, Part 1, entry for Cefaclor in the form Tablet (sustained release) 375 mg (as monohydrate)
         (a)           omit:
         a  APO-Cefaclor CD  TX  PDP        10  0  10

         (b)           omit:
         a  APO-Cefaclor CD  TX  MP        10  1  10

     [26]               Schedule 1, Part 1, entry for Cefazolin in the form Powder for injection 2 g (as sodium)
     omit:
         a  Cefazolin-AFT  AE  MP NP  C5826 C5867 C5881 C5890     10  0  5

     [27]               Schedule 1, Part 1, entry for Cefepime in the form Powder for injection 1 g (as hydrochloride)
     omit:
         a   Cefepime-AFT   AE   MP NP   C5842      10   0   1

     [28]               Schedule 1, Part 1, entry for Ceftriaxone in the form Powder for injection 1 g (as sodium)
     omit:
         a  Ceftriaxone-AFT  AE  MP NP  C5830 C5862 C5868     5  0  1

     [29]               Schedule 1, Part 1, entry for Ceftriaxone in the form Powder for injection 2 g (as sodium)
     omit:
         a  Ceftriaxone-AFT  AE  MP NP  C5826 C5881 C5890     5  0  1

     [30]               Schedule 1, Part 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 50 mg
         (a)           omit:
         a  APO-Cyproterone  TX  MP     P5532  20      5       20
                                               CN5532  CN5532

         (b)           omit:
         a  GenRx Cyproterone Acetate  GX  MP     P5532  20      5       20
                                                         CN5532  CN5532

         (c)           omit:
         a  APO-Cyproterone  TX  MP        100  5  50

         (d)           omit:
         a  GenRx Cyproterone Acetate  GX  MP        100  5  50

     [31]               Schedule 1, Part 1, entry for Cyproterone in the form Tablet containing cyproterone acetate 100 mg
         (a)           omit:
         a  APO-Cyproterone  TX  MP        50  5  50

         (b)           omit:
         a  GenRx Cyproterone Acetate  GX  MP        50  5  50

     [32]               Schedule 1, Part 1, entry for Dabigatran etexilate
     substitute:
Dabigatran etexilate  Capsule 75 mg (as mesilate)   Oral     Pradaxa            BY  MP NP  C4369 C4381 C4402               P4381   20   0  10
                                                                                    MP NP  C4369 C4381 C4402               P4369   20   1  10
                                                          a  ARX-Dabigatran     XT  MP NP  C4402                                   60   0  60
                                                          a  Pradaxa            BY  MP NP  C4369 C4381 C4402               P4402   60   0  60
                      Capsule 110 mg (as mesilate)  Oral     Pradaxa            BY  MP NP  C4269 C4369 C4381 C4402 C14308  P4381   20   0  10
                                                                                    MP NP  C4269 C4369 C4381 C4402 C14308  P4369   20   1  10
                                                          a  ARX-Dabigatran     XT  MP NP  C4269 C4402